Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.

Abstract

Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure. Most cases are linked to gadodiamide. Gadoversetamide, an agent with chelate characteristics similar to gadodiamide, has rarely been described to cause NSF. With the exception of normalization of kidney function, there are no consistently effective therapies for patients with NSF. We describe 3 cases of NSF in patients with end-stage renal disease after gadolinium-based contrast exposure. Two patients received gadoversetamide and the third received gadodiamide. All 3 patients were treated early in their disease course with intravenous sodium thiosulfate and responded with improved skin changes and joint mobility.

• Authors: Deepak Kadiyala, David A Roer, Mark A Perazella
• Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 53 Issue 1 Pg. 133-7 (Jan 2009) ISSN: 1523-6838 [Electronic] United States
• PMID: 19022548 (Publication Type: Case Reports, Journal Article)

Chemical References

• Chelating Agents
• Contrast Media
• Organometallic Compounds
• Thiosulfates
• sodium thiosulfate
• gadoversetamide

Topics

• Adult
• Chelating Agents (pharmacology, therapeutic use)
• Contrast Media (adverse effects)
• Female
• Humans
• Joints (drug effects)
• Male
• Middle Aged
• Nephrogenic Fibrosing Dermopathy (chemically induced, drug therapy)
• Organometallic Compounds (adverse effects)
• Skin (drug effects)
• Thiosulfates (pharmacology, therapeutic use)